Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Support us
Support us
  • Home
  • Lindy Vernooij

Lindy Vernooij

PhD Student

Targeting BCL2 in neuroblastoma

Phone -
Email L.Vernooij-4@prinsesmaximacentrum.nl

Publications

6 publications in total

  • Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine

    • mrt. 2025
    • Karin P.S., Langenberg, et al
    • European Journal of Cancer

  • Preclinical assessment of combined BCL-2 and MCL-1 inhibition in high-risk neuroblastoma

    • jun. 2024
    • Lindy, Vernooij, et al
    • EJC Paediatric Oncology

  • MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

    • jan. 2023
    • Thomas F., Eleveld, et al
    • Frontiers in Oncology

  • MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

    • jan. 2023
    • Thomas F, Eleveld, et al
    • Frontiers in Oncology

  • High-throughput screening identifies idasanutlin as a resensitizing drug for venetoclax-resistant neuroblastoma cells

    • jun. 2021
    • Lindy, Vernooij, et al
    • Molecular Cancer Therapeutics
View all publications